Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.

ABSTRACT:

Background

Metastatic CRC (mCRC) is a molecular heterogeneous disease. The aim of this review is to give an overview of molecular-driven treatment of mCRC patients.

Methods

A review of clinical trials, retrospective studies and case reports was performed regarding molecular biomarkers with therapeutic implications.

Results

RAS wild-type status was confirmed as being crucial for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and for rechallenge strategy. Antiangiogenic therapies improve survival in first- and second-line settings, irrespective of RAS status, while tyrosine kinase inhibitors (TKIs) remain promising in refractory mCRC. Promising results emerged from anti-HER2 drugs trials in HER2-positive mCRC. Target inhibitors were suc

SUBMITTER: Lai E 

PROVIDER: S-EPMC7281737 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature